Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Explore clinical trials studying Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL). Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) trial results

Not Yet Recruiting

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

NCT07725406

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +23 more
Locations: Weill Cornell Medicine/NewYork-Presbyterian Hospital New York, United States

View Trial Details

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT03340766

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: Research Site La Jolla, California, United States

Research Site Charleston, South Carolina, United States

Research Site Greenville, South Carolina, United States

Research Site Darlinghurst, New South Wales, Australia

View all 22 locations

View Trial Details

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) trial results

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Related conditions